Shares of Compass Pathways (NASDAQ:CMPS) lost ~35% in the premarket on Thursday after the psychedelic drug developer, with its Q3 2024 financials, announced plans to lay off staff amid a delay in its ...
Stocktwits on MSN
Psychedelics break out of the fringe under RFK Jr’s 2025 reset — but did MNMD or CMPS own the year?
With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at ...
COMPASS Pathways focuses on developing COMP360 psilocybin for treatment-resistant depression, facing significant challenges due to its Schedule I status. Key risks include market acceptance, ...
COMPASS Pathways plc beats earnings expectations. Reported EPS is $-0.44, expectations were $-0.47. Operator: Ladies and gentlemen, thank you for standing by. And welcome to the COMPASS Pathways First ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today ...
Per the consensus of Wall Street analysts, Compass Pathways (NASDAQ: CMPS) stock is on track for an absolutely stellar 12 months. They see its shares rising by 307% compared to where it is today. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback